National Class Action On Behalf Of Canadian Users Of Rexulti
Proposed Settlement Reached in Rexulti Class Action
August 23, 2025 – On December 3, 2021, the Quebec Superior Court of Justice certified a national class action on behalf of REXULTI® Class Members relating to the Defendant drug manufacturers’ alleged failure to warn of the risks of compulsive gambling, hypersexuality, compulsive shopping, and binge eating (“Compulsive Behaviours”) associated with REXULTI®. Notice of authorization of the Class Action was provided on March 15, 2024. The opt-out deadline for Class Members who did not wish to participate in the Class Action expired on May 15, 2024.
The parties have reached a proposed settlement (the “Settlement”) on behalf of all individuals in Canada who were prescribed and took REXULTI® from February 16, 2017 to today’s date and their family members. The Courts have not made any determination of the merits of the claims. The Defendants have denied, and continue to deny, the allegations against them in the Class Action.
For the Settlement to become effective, Court approval is necessary. The Court must be satisfied that the Settlement is fair, reasonable and in the best interests of Class Members. The Settlement Approval Hearing has been scheduled to be heard before the Superior Court of Québec on October 31, 2025.
Class Members who experienced the Compulsive Behaviours for the first time after May 16, 2024, may still opt-out of the Class Action and exclude themselves from the Settlement by delivering an Opt Out form before October 23, 2025 to the Claims Administrator. Opt Out Forms are available at the link below.
If you experienced the Compulsive Behaviours for the first time prior to May 16, 2024 and did not previously opt out of the class action, you may make a request to the Québec Court to opt out of the Settlement by sending a notice to the clerk of the Superior Court of Quebec at 1 Notre-Dame St. East, Montreal, QC, H2Y 1B6, specifying the Court file no. 500-06-000831-160 and attaching a sworn declaration explaining your reasons. If you do not opt out and the Settlement is approved and becomes effective, you will be bound by the Settlement which includes a release of your claims.
The Short-Form and Long-Form Notices are available at the links below:
The Opt-Out Forms are available in both English and French at the links below:
The judgment of the Honourable Justice Nollet of the Superior Court of Quebec approving the notices and scheduling the Settlement Approval Hearing is available at the link below:
Update: March 4, 2024 – A National Class Action has been authorized by the Superior Court of Quebec on behalf of all persons in Canada who were prescribed and used the prescription antipsychotic drug REXULTI during the Class Period starting from February 16, 2017 and who developed one or more of the following Compulsive Behaviours and Impulse Control Disorders: Compulsive Gambling, Hypersexuality, Binge eating, and Compulsive shopping and/or spending.
If you were prescribed and used REXULTI during the Class Period and developed one or more of the Compulsive Behaviours or Impulse Control Disorders described above, your rights are affected by this action. If you wish to remain in the lawsuit, you don’t need to take any further steps at this time. If you wish to exclude yourself from the lawsuit, you must deliver a signed Opt-Out Form by May 15, 2024 by courier, registered or certified mail, to Clerk of the Superior Court of Quebec, Montreal Courthouse, 1 Notre-Dame Street East, Room 1.120, Montreal (Quebec) H2Y 1B6 and reference Court File No. 500-06-000948-188.
Please see below for links to the relevant documents including the Opt-Out Forms in English and French:
Rexulti Long-Form Notice (English)
Rexulti Short-Form Notice (English)
Rexulti Long-Form Notice (French)
Rexulti Short-Form Notice (French)
Opt-Out Form (English)
Opt-Out Form (French)
Rectified Judgment Approving the Authorization Notices and Notice Plan – Feb. 29, 2024
On October 9, 2018, Rochon Genova and Woods commenced a proposed national class action on behalf of all person in Canada who have been prescribed and ingested the antipsychotic drug Rexulti.
Rexulti is the trademark for the drug, brexpiprazole. Rexulti was approved as treatment for schizophrenia in Canada in February 2017, and as treatment for depression in February 2019.
The claim alleges that Otsuka and Lundbeck – the pharmaceutical companies responsible for developing and marketing Rexulti – failed to provide Canadian uses with adequate and timely warnings about the increased risk of impulse control disorders and compulsive behaviours, such as compulsive gambling, compulsive shopping/spending, hypersexuality and binge-eating.
Rexulti is a partial dopamine agonist that is alleged to be substantially similar to the antipsychotic drug aripiprazole (marketed under the trade names Abilify and Abilify Maintena). Abilify and Abilify Maintena were approved in Canada in 2009 and 2014, and have also been associated with impulse control disorders and compulsive behaviours.
Otsuka developed Abilify and Abilify Maintena and has been commercializing and marketing them in Canada along with Bristol-Myers Squibb Canada Co. and Lundbeck Canada Inc., respectively. The claim alleges that the Otsuka and Lundbeck companies intentionally developed Rexulti to be substantially similar to Abilify, because Abilify was losing patent protection. The similarity in the chemical structures of Rexulti and Abilify/Abilify Maintena was noted in the Health Canada Summary Basis of Decision for Rexulti.
This action was commenced in the Quebec Superior Court of Justice in Montreal. Rochon Genova and Woods are seeking authorization of this action as a class action.
The claims have not yet been proven in court. For more information about this proposed class action, please contact Jon Sloan at 1-866-881-2292 ext. 2990 or [email protected]